Clinical Utility of Implementing a Frontline NGS-Based DNA and RNA Fusion Panel Test for Patients with Suspected Myeloid Malignancies

[1]  C. Howlett,et al.  Reducing cytogenetic testing in the era of next generation sequencing: Are we choosing wisely? , 2021, International journal of laboratory hematology.

[2]  P. Guglielmelli,et al.  Impact of Mutational Profile on the Management of Myeloproliferative Neoplasms: A Short Review of the Emerging Data , 2020, OncoTargets and therapy.

[3]  A. Gerasimova,et al.  Analytical validation and performance characteristics of a 48-gene next-generation sequencing panel for detecting potentially actionable genomic alterations in myeloid neoplasms , 2020, bioRxiv.

[4]  W. Blum,et al.  Treating acute myeloid leukemia in the modern era: A primer , 2020, Cancer.

[5]  A. Trumpp,et al.  Survival differences and associated molecular signatures of DNMT3A-mutant acute myeloid leukemia patients , 2020, Scientific Reports.

[6]  Ping Yang,et al.  Clinical value of next‐generation sequencing compared to cytogenetics in patients with suspected myelodysplastic syndrome , 2020, British journal of haematology.

[7]  P. Johansson,et al.  ASXL1 mutations, previous vascular complications and age at diagnosis predict survival in 85 WHO‐defined polycythaemia vera patients , 2020, British journal of haematology.

[8]  S. Saad,et al.  Co-occurrence of DNMT3A, NPM1, FLT3 mutations identifies a subset of acute myeloid leukemia with adverse prognosis. , 2020, Blood.

[9]  J. Cigudosa,et al.  Spanish Guidelines for the use of targeted deep sequencing in myelodysplastic syndromes and chronic myelomonocytic leukaemia , 2019, British journal of haematology.

[10]  P. Szankasi,et al.  Chronic myelomonocytic leukemia with ETV6-ABL1 rearrangement and SMC1A mutation. , 2019, Cancer genetics.

[11]  H. Feilotter,et al.  Implementation of an NGS‐based sequencing and gene fusion panel for clinical screening of patients with suspected hematologic malignancies , 2019, European journal of haematology.

[12]  E. Fermo,et al.  The Role of New Technologies in Myeloproliferative Neoplasms , 2019, Front. Oncol..

[13]  S. Ogawa.  Genetics of MDS. , 2019, Blood.

[14]  Annette S. Kim,et al.  Clinical Significance of DNA Variants in Chronic Myeloid Neoplasms: A Report of the Association for Molecular Pathology. , 2018, The Journal of molecular diagnostics : JMD.

[15]  U. Amstutz,et al.  Challenges in the introduction of next-generation sequencing (NGS) for diagnostics of myeloid malignancies into clinical routine use , 2018, Blood Cancer Journal.

[16]  Chieh-Yu Liu,et al.  Incorporation of mutations in five genes in the revised International Prognostic Scoring System can improve risk stratification in the patients with myelodysplastic syndrome , 2018, Blood Cancer Journal.

[17]  O. Abdel-Wahab,et al.  Diagnosis and classification of hematologic malignancies on the basis of genetics. , 2017, Blood.

[18]  K. Patel,et al.  Diagnostic, Prognostic, and Predictive Utility of Recurrent Somatic Mutations in Myeloid Neoplasms , 2017, Clinical lymphoma, myeloma & leukemia.

[19]  B. Ebert,et al.  Clinical Implications of Genetic Mutations in Myelodysplastic Syndrome. , 2017, Journal of clinical oncology : official journal of the American Society of Clinical Oncology.

[20]  Bob Löwenberg,et al.  Diagnosis and management of AML in adults: 2017 ELN recommendations from an international expert panel. , 2017, Blood.

[21]  B. Ebert,et al.  The genetics of myelodysplastic syndrome: from clonal haematopoiesis to secondary leukaemia , 2016, Nature Reviews Cancer.

[22]  J. Maciejewski,et al.  Incorporation of molecular data into the Revised International Prognostic Scoring System in treated patients with myelodysplastic syndromes , 2016, Leukemia.

[23]  Nicola D. Roberts,et al.  Genomic Classification and Prognosis in Acute Myeloid Leukemia. , 2016, The New England journal of medicine.

[24]  Mario Cazzola,et al.  The 2016 revision to the World Health Organization classification of myeloid neoplasms and acute leukemia. , 2016, Blood.

[25]  G. Marcucci,et al.  Molecular prognostic factors in cytogenetically normal acute myeloid leukemia , 2012, Expert review of hematology.

[26]  N. Socci,et al.  Prognostic relevance of integrated genetic profiling in acute myeloid leukemia. , 2012, The New England journal of medicine.

[27]  B. Smith,et al.  Prognostically important molecular markers in cytogenetically normal acute myeloid leukemia. , 2011, The American journal of the medical sciences.

[28]  D. Steensma.  Novel therapies for myelodysplastic syndromes. , 2010, Hematology/oncology clinics of North America.

[29]  Marilyn M. Li,et al.  Standards and Guidelines for the Interpretation and Reporting of Sequence Variants in Cancer: A Joint Consensus Recommendation of the Association for Molecular Pathology, American Society of Clinical Oncology, and College of American Pathologists. , 2017, The Journal of molecular diagnostics : JMD.

[30]  H. Deeg,et al.  Myelodysplastic Syndromes, Version 2.2017, NCCN Clinical Practice Guidelines in Oncology. , 2017, Journal of the National Comprehensive Cancer Network : JNCCN.